Prime Medicine, Inc. (Nasdaq: PRME) announced the appointment of Svetlana Makhni as its Chief Financial Officer, effective April 16, 2026. Makhni brings more than two decades of experience in finance and corporate development at clinical‑stage biotechnology companies, most recently serving as CFO of Marengo Therapeutics.
Makhni’s background includes leading financial strategy and capital‑markets activities for Marengo, where she helped secure strategic partnerships with companies such as Ipsen and Gilead Sciences. Her expertise is expected to reinforce Prime Medicine’s financial operations and strategy as the company moves toward the clinic with its Wilson Disease and Alpha‑1 Antitrypsin Deficiency (AATD) programs, both of which are slated to file IND/CTA applications in the first half of 2026 and mid‑2026, respectively, with initial data anticipated in 2027.
Prime Medicine’s Prime Editing platform underpins its pipeline, and the company’s market capitalization stands at $671 million. Despite a negative free cash flow of $167 million over the preceding twelve months, liquid assets exceed short‑term obligations, giving the company financial flexibility to fund operations into 2027. The appointment follows the transition of former CFO Allan Reine, M.D., to the CEO role in May 2025, marking a separation of the CFO and CEO functions.
"We are delighted to welcome Svetlana to Prime Medicine. Svetlana brings proven leadership at clinical‑stage biotechnology companies, as well as deep capital markets expertise. As we prepare to enter the clinic in both Wilson Disease and Alpha‑1 Antitrypsin Deficiency, her leadership will be instrumental in ensuring Prime Medicine is well positioned – both financially and strategically – to execute on the tremendous promise of Prime Editing for patients with Wilson Disease, AATD and beyond," said CEO Allan Reine.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.